Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. Santos Raul D et al. The New England journal of medicine 2020 10 (14) 1317-1327

Hot Topics of the Day|PHGKB

 Familial Hypercholesterolemia

Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
Santos Raul D et al. The New England journal of medicine 2020 10 (14) 1317-1327

In this trial involving pediatric patients with familial hypercholesterolemia, evolocumab reduced the LDL cholesterol level and other lipid variables. 157 patients underwent randomization and received evolocumab (104 patients) or placebo (53 patients). At week 24, the mean difference was -38.3 percentage points.